Overall, the present study results indicate that TLF-II treatment effectively reduced bladder injury and bacterial load in mice, decreased the levels of TLR4 and NF-κB, as well as the expression of inflammatory factors IL-1β and IL-6, and suppressed UTI-induced inflammation. This evidence concerns the gene IL6 and bacterial urinary tract infection.